Cadonilimab Shows Superiority Over PD-1 Inhibitors for PD-L1-Low Gastric Cancer A recent study reveals that Cadonilimab significantly outperforms PD-1 inhibitors in treating advanced gastric cancer with PD-L1 low levels, enhancing survival rates.

Cadonilimab Shows Superiority Over PD-1 Inhibitors for PD-L1-Low Gastric Cancer #Hong_Kong #Cadonilimab #Advanced_Gastric_Cancer #PD-1_Inhibitors